A CONTROLLED TRIAL OF ISONIAZID PROPHYLAXIS INMENTAL INSTITUTIONS

Publisher Website
Google Scholar
Abstract
Isoniazid was given daily for 12 mo. (average dose of approximately 5 mg/kg of body weight) to mental patients. Intercurrent illness occurred with the same frequency in the placebo and isoniazid-treated groups. In the infected adult population, the risk of the quiescent lesion becoming active was much greater among men than women. For both sexes, the risk increased with age and was greater among those who weighed less. No isoniazid-resistant tubercle bacilli developed. The trial confirms the effectiveness of isoniazid prophylaxis.

This publication has 4 references indexed in Scilit: